APA

Bavisotto L. M., Ellis D. J., Milner P. G., Combs D. L., Irwin I. & Canafax D. M. (20110714). Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. : Journal of clinical pharmacology.

Chicago

Bavisotto Linda M, Ellis David J, Milner Peter G, Combs Daniel L, Irwin Ian and Canafax Daniel M. 20110714. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. : Journal of clinical pharmacology.

Harvard

Bavisotto L. M., Ellis D. J., Milner P. G., Combs D. L., Irwin I. and Canafax D. M. (20110714). Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. : Journal of clinical pharmacology.

MLA

Bavisotto Linda M, Ellis David J, Milner Peter G, Combs Daniel L, Irwin Ian and Canafax Daniel M. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. : Journal of clinical pharmacology. 20110714.